Bicycle Therapeutics (BCYC) EBIT (2018 - 2025)
Historic EBIT for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$65.6 million.
- Bicycle Therapeutics' EBIT fell 267.05% to -$65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$290.0 million, marking a year-over-year decrease of 4763.49%. This contributed to the annual value of -$209.9 million for FY2024, which is 1049.03% down from last year.
- Latest data reveals that Bicycle Therapeutics reported EBIT of -$65.6 million as of Q3 2025, which was down 267.05% from -$86.6 million recorded in Q2 2025.
- Bicycle Therapeutics' EBIT's 5-year high stood at -$14.3 million during Q3 2021, with a 5-year trough of -$86.6 million in Q2 2025.
- Over the past 5 years, Bicycle Therapeutics' median EBIT value was -$41.8 million (recorded in 2023), while the average stood at -$42.3 million.
- In the last 5 years, Bicycle Therapeutics' EBIT skyrocketed by 2412.98% in 2024 and then plummeted by 12135.2% in 2025.
- Quarter analysis of 5 years shows Bicycle Therapeutics' EBIT stood at -$18.0 million in 2021, then crashed by 78.71% to -$32.2 million in 2022, then tumbled by 68.37% to -$54.2 million in 2023, then decreased by 24.76% to -$67.7 million in 2024, then grew by 3.12% to -$65.6 million in 2025.
- Its EBIT stands at -$65.6 million for Q3 2025, versus -$86.6 million for Q2 2025 and -$70.2 million for Q1 2025.